Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Hypomethylation of DNA in pathological conditions of the human prostate.

Bedford MT, van Helden PD.

Cancer Res. 1987 Oct 15;47(20):5274-6.

2.

Reduced genomic 5-methylcytosine content in human colonic neoplasia.

Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M.

Cancer Res. 1988 Mar 1;48(5):1159-61.

3.

DNA methylation levels in acute human leukemia.

Pfeifer GP, Steigerwald S, Boehm TL, Drahovsky D.

Cancer Lett. 1988 Mar;39(2):185-92.

PMID:
3359414
4.
5.

DNA hypomethylation in Morris hepatomas.

Lu LJ, Randerath E, Randerath K.

Cancer Lett. 1983 Jun;19(2):231-9.

PMID:
6192902
6.
7.

Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.

Singal R, Ferdinand L, Reis IM, Schlesselman JJ.

Oncol Rep. 2004 Sep;12(3):631-7.

PMID:
15289848
8.

Multigene methylation analysis for detection and staging of prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

9.

Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.

Paradowska A, Fenic I, Konrad L, Sturm K, Wagenlehner F, Weidner W, Steger K.

Int J Oncol. 2009 Jul;35(1):87-96.

PMID:
19513555
10.

PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.

Koch P, Petri M, Paradowska A, Stenzinger A, Sturm K, Steger K, Wimmer M.

Prostate. 2009 Dec 1;69(16):1751-62. doi: 10.1002/pros.21025.

PMID:
19691131
11.

p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.

Parsons JK, Gage WR, Nelson WG, De Marzo AM.

Urology. 2001 Oct;58(4):619-24.

PMID:
11597556
12.
13.

Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants.

Flatau E, Bogenmann E, Jones PA.

Cancer Res. 1983 Oct;43(10):4901-5.

14.

The relationship between 8-oxo-7,8-dihydro-2'-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas.

Guz J, Foksinski M, Siomek A, Gackowski D, Rozalski R, Dziaman T, Szpila A, Olinski R.

Mutat Res. 2008 Apr 2;640(1-2):170-3. doi: 10.1016/j.mrfmmm.2007.12.013.

PMID:
18281064
15.

Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.

Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI.

J Natl Cancer Inst. 1998 Sep 2;90(17):1284-91.

PMID:
9731735
16.

Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium.

Woessner RD, Wright PS, Loudy DE, Wallace CD, Montgomery LR, Nestok BR.

Exp Mol Pathol. 1998;65(1):37-52.

PMID:
9613925
17.

High frequency of alterations in DNA methylation in adenocarcinoma of the prostate.

Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA.

Prostate. 1999 May 15;39(3):166-74.

PMID:
10334105
18.

A quantitative promoter methylation profile of prostate cancer.

Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D.

Clin Cancer Res. 2004 Dec 15;10(24):8472-8.

19.

Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue.

Morton RA Jr, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB.

J Urol. 1996 Aug;156(2 Pt 1):512-6.

PMID:
8683727
20.

Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue.

Lin VK, Wang D, Lee IL, Vasquez D, Fagelson JE, McConnell JD.

Prostate. 2000 Aug 1;44(3):193-203.

PMID:
10906735

Supplemental Content

Support Center